313 related articles for article (PubMed ID: 32871242)
1. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients.
Hogan Ii RB; Hogan Iii RB; Cannon T; Rappai M; Studdard J; Paul D; Dooley TP
Pulm Pharmacol Ther; 2020 Aug; 63():101942. PubMed ID: 32871242
[TBL] [Abstract][Full Text] [Related]
2. Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
Freedberg DE; Conigliaro J; Wang TC; Tracey KJ; Callahan MV; Abrams JA;
Gastroenterology; 2020 Sep; 159(3):1129-1131.e3. PubMed ID: 32446698
[No Abstract] [Full Text] [Related]
3. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Janowitz T; Gablenz E; Pattinson D; Wang TC; Conigliaro J; Tracey K; Tuveson D
Gut; 2020 Sep; 69(9):1592-1597. PubMed ID: 32499303
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria.
Wan KS
J Dermatolog Treat; 2009; 20(4):194-7. PubMed ID: 19085267
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial.
Samimagham HR; Hassani Azad M; Haddad M; Arabi M; Hooshyar D; KazemiJahromi M
Trials; 2020 Oct; 21(1):848. PubMed ID: 33050945
[TBL] [Abstract][Full Text] [Related]
7. Famotidine Against SARS-CoV2: A Hope or Hype?
Ghosh R; Chatterjee S; Dubey S; Lavie CJ
Mayo Clin Proc; 2020 Aug; 95(8):1797-1799. PubMed ID: 32753153
[No Abstract] [Full Text] [Related]
8. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
9. Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19.
Mather JF; Seip RL; McKay RG
Am J Gastroenterol; 2020 Oct; 115(10):1617-1623. PubMed ID: 32852338
[TBL] [Abstract][Full Text] [Related]
10. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
11. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
12. Anti-histamines and Covid-19: Hype or Hope.
Al-Kuraishy HM; Al-Rubiey HF; Al-Buhadily AK; Al-Gareeb AI
J Pak Med Assoc; 2021 Dec; 71(Suppl 8)(12):S144-S148. PubMed ID: 35130238
[TBL] [Abstract][Full Text] [Related]
13. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
14. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
15. Histamine receptors and COVID-19.
Ennis M; Tiligada K
Inflamm Res; 2021 Jan; 70(1):67-75. PubMed ID: 33206207
[TBL] [Abstract][Full Text] [Related]
16. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
Quirch M; Lee J; Rehman S
J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
18. Δ9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression.
Mohammed A; F K Alghetaa H; Miranda K; Wilson K; P Singh N; Cai G; Putluri N; Nagarkatti P; Nagarkatti M
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872332
[TBL] [Abstract][Full Text] [Related]
19. A rationale for targeting the P2X7 receptor in Coronavirus disease 19.
Di Virgilio F; Tang Y; Sarti AC; Rossato M
Br J Pharmacol; 2020 Nov; 177(21):4990-4994. PubMed ID: 32441783
[TBL] [Abstract][Full Text] [Related]
20. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.
Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A
Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
